NCT01721915View on ClinicalTrials.gov

Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism

PHASE4CompletedINTERVENTIONAL

Enrollment

330

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 12, 2017

Study Completion Date

October 12, 2017

Conditions

Polycystic Ovary SyndromeHealthyVitamin D Deficiency

Interventions

DRUG

Vitamin D supplementation

The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)

DRUG

Placebo

Trial Locations (1)

8036

Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism, Graz

All Listed Sponsors

collaborator

Austrian Science Fund (FWF)

OTHER

lead

Medical University of Graz

OTHER

NCT01721915 - Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism | Biotech Hunter | Biotech Hunter